BU7-62469-74443
3 vaccinations
4 coded responses
10 check-ins
4 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 56-60
- ZIP prefix
- 315 / GA
- Registered
- 2021-03-19
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-19
Registered in v-safe
-
2021-03-19
Dose 1 — Pfizer-BioNTech
-
2021-03-21
Survey response — days 1–6 daily, dose 1MedDRA: Headache, Injection site pain, Injection site pruritus, Tenderness — Feeling: Good · Rash, not including the immediate area around the injection siteFree text: First day pain at injection site, headache and itching. Second day just tender and no itching or headache. Third day no pain.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-22
- 2021-03-23
- 2021-03-26
- 2021-04-02
-
2021-04-12
Dose 2 — Pfizer-BioNTech
-
2021-04-16
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Chills, Fatigue or tiredness, NauseaAdult check-in
-
2021-04-26
Survey response — day 14, dose 2MedDRA: Meningitis — Feeling: Poor · Be unable to workFree text: MeningitisMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-08-20
Dose 3 — Pfizer-BioNTech
-
2021-10-11
Survey response — 6 months, dose 2MedDRA: Drug hypersensitivity, Hepatic enzyme increased, Impaired healing, Skin ulcer — Feeling: Poor · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visitFree text: Issues with toe ulcers that will not heal. Allergic reactions to antibiotics never experienced before. In addition, elevated liver counts. All issues - doctors have been unable to determine root cause.MedDRA releases: 2024-11 · check-in free text available
-
2021-10-11
Report sent to call center — 6 months, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
- 2021-10-12
-
2022-02-18
Survey response — 6 months, dose 3MedDRA: Angiopathy, Unevaluable event, Vascular occlusion, Vascular pain — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Vasculopathy - undetermined cause limiting mobility and reflecting blockage, pain and inflammation.MedDRA releases: 2024-11 · check-in free text available
-
2022-02-18
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-02-21
Call successfulDoes not wish to fill out VAERS report
- 2022-08-22
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-19 | Pfizer-BioNTech | |
| 2 | 2021-04-12 | Pfizer-BioNTech | |
| 3 | 2021-08-20 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 successful
Free text
Release 6 — days 1–6 daily, dose 1
Systemic reaction (other): First day pain at injection site, headache and itching. Second day just tender and no itching or headache. Third day no pain.
Release 8 — day 14, dose 2
Symptoms: Meningitis
Release 10 — 6 months, dose 2
Symptoms: Issues with toe ulcers that will not heal. Allergic reactions to antibiotics never experienced before. In addition, elevated liver counts. All issues - doctors have been unable to determine root cause.
Release 11 — 6 months, dose 3
Symptoms: Vasculopathy - undetermined cause limiting mobility and reflecting blockage, pain and inflammation.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Angiopathy | · | · | ✓ |
| SD | Drug hypersensitivity | · | · | ✓ |
| SD | Hepatic enzyme increased | · | · | ✓ |
| SD | Impaired healing | · | · | ✓ |
| SD | Meningitis | ✓ | ✓ | ✓ |
| SD | Skin ulcer | · | · | ✓ |
| SD | Unevaluable event | · | · | ✓ |
| SD | Vascular occlusion | · | · | ✓ |
| SD | Vascular pain | · | · | ✓ |
| SRO | Headache | ✓ | ✓ | ✓ |
| SRO | Injection site pain | ✓ | ✓ | ✓ |
| SRO | Injection site pruritus | ✓ | ✓ | ✓ |
| SRO | Tenderness | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release